Maintenance Therapies Fail in Ovarian Cancer

Maintenance Therapies Fail in Ovarian Cancer
Erlotinib produces no benefit; PARP inhibitor olaparib produces modest PFS improvement

Chicago—After front-line chemotherapy, maintenance erlotinib (Tarceva, Genentech) failed to show any significant benefit in patients with ovarian cancer, according to results of a Phase III trial presented at the 2012 annual meeting of the American Society of Clinical Oncology (abstract LBA5000).

If the link below does not open, please copy and past this link into your browser:
http://www.clinicaloncology.com/ViewArticle.aspx?d=Solid+Tumors&d_id=148&i=September+2012&i_id=887&a_id

Clinical Oncology News
http://www.clinicaloncology.com